Adlai Nortye Ltd. ADR (N2U0)
XSTU 
Summary
N2U0 Chart
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Adlai Nortye Ltd. ADR (N2U0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Adlai Nortye Ltd. ADR ever had a stock split?
Adlai Nortye Ltd. ADR Profile
| Biotechnology Industry | Healthcare Sector | Yang Lu CEO | XSTU Exchange | US00704R1095 ISIN |
| KY Country | 123 Employees | - Last Dividend | - Last Split | 29 Sep 2023 IPO Date |
Overview
Adlai Nortye Ltd. is a forward-thinking clinical-stage biotechnology company primarily engaged in the discovery and development of innovative cancer therapies. With key operations across the United States and Mainland China, the company is committed to addressing the urgent needs of cancer patients through the advancement of its pipeline products. Founded in 2018 and headquartered in Grand Cayman, the Cayman Islands, Adlai Nortye is at the forefront of oncological research, focusing on treatments that could revolutionize the approach to cancer care.
Products and Services
-
AN2025:
This leading product is a pan-phosphoinositide 3-kinase (PI3K) inhibitor currently in a Phase III clinical trial aimed at treating recurrent or metastatic head and neck squamous cell carcinomas. The drug represents a cutting-edge approach in targeting specific pathways implicated in cancer progression.
-
AN0025:
A small molecule EP4 antagonist designed to modulate the tumor microenvironment. By targeting specific signaling pathways, AN0025 seeks to hinder the progression of tumors, marking a significant step forward in cancer treatment.
-
AN4005:
An oral small-molecule PD-L1 inhibitor that works by inducing and stabilizing PD-L1 dimerization, disrupting the interaction between PD-1 and PD-L1. This innovative mechanism of action has the potential to enhance the immune system's ability to fight cancer.
-
Preclinical candidates:
AN8025: A multifunctional antibody aimed at modulating T cells and antigen-presenting cells (APCs), suggesting a novel method of engaging the immune system in the fight against cancer.
AN1025: An oral small molecule designed to degrade ß-catenin, a protein often implicated in the proliferation of cancer cells, representing a new avenue for cancer therapy.
AN9025: An oral small molecule pan-KRAS inhibitor, targeting a wider range of the KRAS mutations known to drive cancer growth, and presenting a promising new strategy in the battle against cancer.
Contact Information
